Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emiliem has entered into an exclusive licensing agreement with the National Institutes of Health for the world-wide rights to develop and commercialize a series of compounds that modulate key biological pathways known to be important in the progression of cancer and other proliferative and inflammatory diseases.
Subscribe to our email newsletter
The lead compound, which is positioned for clinical trials within a year, targets a key mechanism that determines whether cells, particularly those in tumors, grow and proliferate.
Dale Johnson, president and CEO of Emiliem, said: “This is a seminal moment in the history of our company. Not only do we gain a well-researched molecule at an advanced preclinical stage, but this also enables us to focus our internal discovery efforts including medicinal chemistry and early stage development activities around the PI3K/Akt/mTOR pathway, a series of biological events that control protein synthesis, angiogenesis, and cell cycle progression.”